{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T21:49:24Z","timestamp":1768513764933,"version":"3.49.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Otsuka Pharmaceuticals"}],"content-domain":{"domain":["translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.trsl.2014.11.003","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T01:29:43Z","timestamp":1416187783000},"page":"488-498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Novel therapeutic approaches to autosomal dominant polycystic kidney disease"],"prefix":"10.1016","volume":"165","author":[{"given":"Wells B.","family":"LaRiviere","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria V.","family":"Irazabal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2014.11.003_bib1","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2014.11.003_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/71724","article-title":"Cardiac defects and renal failure in mice with targeted mutations in Pkd2","volume":"24","author":"Wu","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.trsl.2014.11.003_bib3","doi-asserted-by":"crossref","first-page":"R356","DOI":"10.1016\/S0960-9822(01)00193-2","article-title":"Human disease: calcium signaling in poylcystic kidney disease","volume":"11","author":"Somlo","year":"2001","journal-title":"Curr Biol"},{"key":"10.1016\/j.trsl.2014.11.003_bib4","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.bbadis.2010.11.005","article-title":"Cyclic AMP-mediated cyst expansion","volume":"1812","author":"Wallace","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.trsl.2014.11.003_bib5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib6","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2014.11.003_bib7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1573402111309010002","article-title":"Cardiovascular complications in autosomal dominant polycystic kidney disease","volume":"9","author":"Ecder","year":"2013","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.trsl.2014.11.003_bib9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2215\/CJN.04310709","article-title":"The HALT polycystic kidney disease trials: design and implementation","volume":"5","author":"Chapman","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/ki.2011.411","article-title":"Analysis of baseline parameters in the HALT polycystic kidney disease trials","volume":"81","author":"Torres","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2014.11.003_bib11","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1681\/ASN.2006121387","article-title":"Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease","volume":"18","author":"Rossetti","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2014.11.003_bib13","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1097\/01.ASN.0000013300.11876.37","article-title":"The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease","volume":"13","author":"Rossetti","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/1573402111309010007","article-title":"The genetics of vascular complications in autosomal dominant polycystic kidney disease (ADPKD)","volume":"9","author":"Rossetti","year":"2013","journal-title":"Curr hypertens Rev"},{"key":"10.1016\/j.trsl.2014.11.003_bib15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/ki.2011.370","article-title":"A missense mutation in PKD1 attenuates the severity of renal disease","volume":"81","author":"Pei","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2014.11.003_bib16","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1006\/bbrc.2001.4554","article-title":"Polycystin-2 is a novel cation channel implicated in defective intracellular Ca(2+) homeostasis in polycystic kidney disease","volume":"282","author":"Vassilev","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.trsl.2014.11.003_bib18","doi-asserted-by":"crossref","first-page":"29488","DOI":"10.1074\/jbc.M504359200","article-title":"Organic cation permeation through the channel formed by polycystin-2","volume":"280","author":"Anyatonwu","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trsl.2014.11.003_bib19","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1097\/01.ASN.0000029587.47950.25","article-title":"The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia","volume":"13","author":"Yoder","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ncb754","article-title":"Polycystin-2 is an intracellular calcium release channel","volume":"4","author":"Koulen","year":"2002","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.trsl.2014.11.003_bib21","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1681\/ASN.V115814","article-title":"Cellular and subcellular distribution of polycystin-2, the protein product of the PKD2 gene","volume":"11","author":"Foggensteiner","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib22","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1159\/000330080","article-title":"Polycystin-1, 2, and STIM1 interact with IP(3)R to modulate ER Ca release through the PI3K\/Akt pathway","volume":"27","author":"Santoso","year":"2011","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.trsl.2014.11.003_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ng1076","article-title":"Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells","volume":"33","author":"Nauli","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.trsl.2014.11.003_bib24","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1161\/CIRCULATIONAHA.107.710111","article-title":"Endothelial cilia are fluid shear sensors that regulate calcium signaling and nitric oxide production through polycystin-1","volume":"117","author":"Nauli","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.trsl.2014.11.003_bib25","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1053\/j.gastro.2006.07.003","article-title":"Cholangiocyte cilia detect changes in luminal fluid flow and transmit them into intracellular Ca2+ and cAMP signaling","volume":"131","author":"Masyuk","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.trsl.2014.11.003_bib26","doi-asserted-by":"crossref","first-page":"6454","DOI":"10.1073\/pnas.0610324104","article-title":"Regulation of ryanodine receptor-dependent calcium signaling by polycystin-2","volume":"104","author":"Anyatonwu","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2014.11.003_bib27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12832","article-title":"Direct recording and molecular identification of the calcium channel of primary cilia","volume":"504","author":"DeCaen","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2014.11.003_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nature12833","article-title":"Primary cilia are specialized calcium signalling organelles","volume":"504","author":"Delling","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2014.11.003_bib29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1681\/ASN.2005060645","article-title":"Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells","volume":"17","author":"Yamaguchi","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.yjmcc.2013.01.015","article-title":"Polycystin-2 mutations lead to impaired calcium cycling in the heart and predispose to dilated cardiomyopathy","volume":"58","author":"Paavola","year":"2013","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.trsl.2014.11.003_bib31","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3\u2032,5\u2032-cyclic monophosphate","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.trsl.2014.11.003_bib32","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1161\/01.RES.0000163278.68142.8a","article-title":"[Ca2+]i reduction increases cellular proliferation and apoptosis in vascular smooth muscle cells: relevance to the ADPKD phenotype","volume":"96","author":"Kip","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.trsl.2014.11.003_bib33","doi-asserted-by":"crossref","first-page":"C1409","DOI":"10.1152\/ajpcell.00408.2006","article-title":"Altered pH(i) regulation and Na(+)\/HCO3(-) transporter activity in choroid plexus of cilia-defective Tg737(orpk) mutant mouse","volume":"292","author":"Banizs","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.trsl.2014.11.003_bib34","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/hep.24723","article-title":"Altered store operated calcium entry increases cyclic 3\u2032,5\u2032-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes","volume":"55","author":"Spirli","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.trsl.2014.11.003_bib35","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1172\/JCI108088","article-title":"Stimulation of osmotic water flow in toad bladder by prostaglandin E1. Evidence for different compartments of cyclic AMP","volume":"56","author":"Flores","year":"1975","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2014.11.003_bib36","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1681\/ASN.2013010077","article-title":"Adenylyl cyclase 6 deficiency ameliorates polycystic kidney disease","volume":"25","author":"Rees","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib37","first-page":"1A","article-title":"Regulation of renal cyst formation by phosphodiesterase 1a in zebrafish","volume":"1A","author":"Sussman","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib38","first-page":"239A","article-title":"Genetic approach to evaluate the role of PDE3 subfamilies in polycystic kidney disease","volume":"23","author":"Ye","year":"2012","journal-title":"[Abstract] J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ki.2011.87","article-title":"WNT\/beta-catenin signaling in polycystic kidney disease","volume":"80","author":"Wuebken","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2014.11.003_bib40","doi-asserted-by":"crossref","first-page":"9971","DOI":"10.1074\/jbc.M508778200","article-title":"Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase","volume":"281","author":"Taurin","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trsl.2014.11.003_bib41","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.molmed.2010.05.004","article-title":"Cystic kidney disease: the role of Wnt signaling","volume":"16","author":"Lancaster","year":"2010","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.trsl.2014.11.003_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ydbio.2012.01.014","article-title":"A protein kinase A and Wnt-dependent network regulating an intermediate stage in epithelial tubulogenesis during kidney development","volume":"364","author":"Gallegos","year":"2012","journal-title":"Dev Biol"},{"key":"10.1016\/j.trsl.2014.11.003_bib43","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJM199307293290503","article-title":"The secretion of fluid by renal cysts from patients with autosomal dominant polycystic kidney disease","volume":"329","author":"Ye","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2014.11.003_bib44","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s00467-006-0355-4","article-title":"Role of kidney chloride channels in health and disease","volume":"22","author":"Veizis","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib45","first-page":"S93","article-title":"Mechanisms of progression in autosomal dominant polycystic kidney disease","volume":"63","author":"Grantham","year":"1997","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.trsl.2014.11.003_bib46","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1152\/physrev.1998.78.4.1165","article-title":"Epithelial transport in polycystic kidney disease","volume":"78","author":"Sullivan","year":"1998","journal-title":"Physiol Rev"},{"key":"10.1016\/j.trsl.2014.11.003_bib47","doi-asserted-by":"crossref","first-page":"F1176","DOI":"10.1152\/ajprenal.00130.2012","article-title":"Impact of the cystic fibrosis mutation F508del-CFTR on renal cyst formation and growth","volume":"303","author":"Li","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.trsl.2014.11.003_bib48","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0272-6386(98)70072-1","article-title":"Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease","volume":"32","author":"O'Sullivan","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trsl.2014.11.003_bib49","first-page":"529","article-title":"Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis","volume":"19","author":"Xu","year":"2006","journal-title":"J Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib50","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1681\/ASN.V1171179","article-title":"cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells","volume":"11","author":"Hanaoka","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib51","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1523-1755.2000.00991.x","article-title":"cAMP stimulates the in\u00a0vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway","volume":"57","author":"Yamaguchi","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2014.11.003_bib52","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/MCB.01259-08","article-title":"Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1","volume":"29","author":"Distefano","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.trsl.2014.11.003_bib53","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1053\/j.gastro.2009.09.005","article-title":"ERK1\/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice","volume":"138","author":"Spirli","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.trsl.2014.11.003_bib54","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1083\/jcb.201306041","article-title":"Where is mTOR and what is it doing there?","volume":"203","author":"Betz","year":"2013","journal-title":"J Cell Biol"},{"key":"10.1016\/j.trsl.2014.11.003_bib55","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00109-012-0902-3","article-title":"Polycystin-1 regulates amphiregulin expression through CREB and AP1 signalling: implications in ADPKD cell proliferation","volume":"90","author":"Aguiari","year":"2012","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.trsl.2014.11.003_bib56","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1681\/ASN.2011030277","article-title":"c-Met and NF-kappaB-dependent overexpression of Wnt7a and -7b and Pax2 promotes cystogenesis in polycystic kidney disease","volume":"23","author":"Qin","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib57","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1681\/ASN.2013091026","article-title":"The cleaved cytoplasmic tail of polycystin-1 regulates Src-dependent STAT3 activation","volume":"25","author":"Talbot","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib58","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0011-5029(05)80007-0","article-title":"Polycystic kidney disease: etiology, pathogenesis, and treatment","volume":"41","author":"Martinez","year":"1995","journal-title":"Dis Mon"},{"key":"10.1016\/j.trsl.2014.11.003_bib59","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3960\/jslrt.53.127","article-title":"Role of Stat3 activation in cell-cell interaction between B-cell lymphoma and macrophages: the in\u00a0vitro study","volume":"53","author":"Bai","year":"2013","journal-title":"J Clin Exp Hematop"},{"key":"10.1016\/j.trsl.2014.11.003_bib60","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1681\/ASN.2011010084","article-title":"Macrophages promote cyst growth in polycystic kidney disease","volume":"22","author":"Karihaloo","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib61","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/ki.2012.446","article-title":"Macrophages promote polycystic kidney disease progression","volume":"83","author":"Swenson-Fields","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2014.11.003_bib62","first-page":"457","article-title":"Histogenesis of the renal cysts in adult (autosomal dominant) polycystic kidney disease: a histochemical study","volume":"1","author":"Verani","year":"1988","journal-title":"Mod Pathol"},{"key":"10.1016\/j.trsl.2014.11.003_bib63","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2014.11.003_bib64","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2014.11.003_bib65","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1681\/ASN.2006030251","article-title":"Increased water intake decreases progression of polycystic kidney disease in the PCK rat","volume":"17","author":"Nagao","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib66","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(67)90098-8","article-title":"Hereditary hypothalamic diabetes insipidus in rats (Brattleboro strain). A useful experimental model","volume":"42","author":"Valtin","year":"1967","journal-title":"Am J Med"},{"key":"10.1016\/j.trsl.2014.11.003_bib67","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib68","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib69","article-title":"Phase 2 Open-Label study to determine long-term safety, tolerability and efficacy of split-dose tolvaptan in ADPKD","volume":"20","author":"Torres","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib70","article-title":"An open-label long term administration study of tolvaptan in patients with ADPKD in Japan","volume":"20","author":"Higashihaha","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib71","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2014.11.003_bib72","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0014-5793(86)81180-2","article-title":"Somatostatin and alpha 2-adrenergic agonists selectively inhibit vasopressin-induced cyclic AMP accumulation in MDCK cells","volume":"198","author":"Friedlander","year":"1986","journal-title":"FEBS Lett"},{"key":"10.1016\/j.trsl.2014.11.003_bib73","first-page":"8","article-title":"Effect of somatostatin on vasopressin-induced antidiuresis and renal cyclic AMP of rats","volume":"7","author":"Winkler","year":"1982","journal-title":"Miner Electrolyte Metab"},{"key":"10.1016\/j.trsl.2014.11.003_bib74","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/0016-5085(95)90157-4","article-title":"Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition","volume":"108","author":"Tan","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.trsl.2014.11.003_bib75","first-page":"1574","article-title":"Somatostatin analogue (octreotide) inhibits bile duct epithelial cell proliferation and fibrosis after extrahepatic biliary obstruction","volume":"143","author":"Tracy","year":"1993","journal-title":"Am J Pathol"},{"key":"10.1016\/j.trsl.2014.11.003_bib76","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/1573402111309010008","article-title":"Experimental therapies and ongoing clinical trials to slow down progression of ADPKD","volume":"9","author":"Irazabal","year":"2013","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.trsl.2014.11.003_bib77","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.26140","article-title":"Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases","volume":"58","author":"Masyuk","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.trsl.2014.11.003_bib78","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2014.11.003_bib79","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2215\/CJN.05380709","article-title":"Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide","volume":"5","author":"Caroli","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib80","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.trsl.2014.11.003_bib81","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","article-title":"The long-term outcome of patients with polycystic liver disease treated with lanreotide","volume":"35","author":"Chrispijn","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.trsl.2014.11.003_bib82","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib83","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","article-title":"Somatostatin analog therapy for severe polycystic liver disease: results after 2 years","volume":"27","author":"Hogan","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trsl.2014.11.003_bib84","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2013.03.004","article-title":"Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial","volume":"59","author":"Chrispijn","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.trsl.2014.11.003_bib85","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of long acting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2014.11.003_bib86","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1053\/j.ajkd.2013.10.011","article-title":"Rationale and Design of the DIPAK 1 Study: a randomized controlled clinical trial assessing the efficacy of lanreotide to halt disease progression in autosomal dominant polycystic kidney disease","volume":"63","author":"Meijer","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trsl.2014.11.003_bib87","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1046\/j.1523-1755.1999.00659.x","article-title":"Polycystin-1 expression in PKD1, early-onset PKD1, and TSC2\/PKD1 cystic tissue","volume":"56","author":"Ong","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2014.11.003_bib88","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/hmg\/8.10.1861","article-title":"Autosomal dominant polycystic kidney disease: clues to pathogenesis","volume":"8","author":"Harris","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.trsl.2014.11.003_bib89","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/ndt\/12.9.1900","article-title":"A large TSC2 and PKD1 gene deletion is associated with renal and extrarenal signs of autosomal dominant polycystic kidney disease","volume":"12","author":"Longa","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trsl.2014.11.003_bib90","doi-asserted-by":"crossref","first-page":"e9239","DOI":"10.1371\/journal.pone.0009239","article-title":"Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR","volume":"5","author":"Dere","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2014.11.003_bib91","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1093\/ndt\/gfp129","article-title":"Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD)","volume":"24","author":"Zafar","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trsl.2014.11.003_bib92","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2014.11.003_bib93","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1681\/ASN.2007050626","article-title":"Sirolimus reduces polycystic liver volume in ADPKD patients","volume":"19","author":"Qian","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib94","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ndt\/gfi181","article-title":"Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)","volume":"21","author":"Wahl","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trsl.2014.11.003_bib95","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/ndt\/gfq384","article-title":"Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats","volume":"26","author":"Renken","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trsl.2014.11.003_bib96","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.2011040340","article-title":"Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease","volume":"23","author":"Novalic","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib97","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/j.1600-6143.2010.03152.x","article-title":"Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: what is the appropriate serum level?","volume":"10","author":"Canaud","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trsl.2014.11.003_bib98","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","article-title":"Sirolimus therapy to half the progression of ADPKD","volume":"21","author":"Perico","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib99","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1093\/ndt\/gfs264","article-title":"Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study","volume":"27","author":"Stallone","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trsl.2014.11.003_bib100","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2014.11.003_bib101","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2014.11.003_bib102","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2215\/CJN.02650313","article-title":"Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study","volume":"9","author":"Braun","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib103","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1681\/ASN.2007060665","article-title":"Src inhibition ameliorates polycystic kidney disease","volume":"19","author":"Sweeney","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2014.11.003_bib104","doi-asserted-by":"crossref","first-page":"C522","DOI":"10.1152\/ajpcell.00163.2010","article-title":"c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation","volume":"301","author":"Elliott","year":"2011","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.trsl.2014.11.003_bib105","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in Pediatric Autosomal Dominant Polycystic Kidney Disease","volume":"9","author":"Cadnapaphornchai","year":"2014","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524414004198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524414004198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T16:53:49Z","timestamp":1650646429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524414004198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1931524414004198"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2014.11.003","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapeutic approaches to autosomal dominant polycystic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2014.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}